Respiratory Tract Neoplasms

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients

Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

PALACE: Cemiplimab Trial According to ctDNA Levels

Real World Registry for Use of the Ion Endoluminal System

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Early Intervention Strategies for Lung Cancer

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

International Lung Screen Trial (ILST)

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Alberta Lung Cancer Screening Program